Sage Therapeutics (SAGE)
(Delayed Data from NSDQ)
$8.41 USD
+0.22 (2.69%)
Updated Aug 23, 2024 03:59 PM ET
After-Market: $8.40 -0.01 (-0.12%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth C Momentum D VGM
Price, Consensus and EPS Surprise
SAGE 8.41 +0.22(2.69%)
Will SAGE be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for SAGE based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for SAGE
Biogen (BIIB) Q2 Earnings & Sales Beat, 2024 Guidance Raised
Sage Therapeutics (SAGE) Q2 Loss Wider Than Expected, Sales Rise
SAGE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Sage Therapeutics, Inc. (SAGE) Reports Q2 Loss, Tops Revenue Estimates
Pacira (PCRX) Q2 Earnings and Revenues Surpass Estimates
What Awaits Biogen (BIIB) in Q2 Earnings Post Leqembi Setback?
Other News for SAGE
Sage Therapeutics price target lowered by $5 at Truist, here's why
SAGE Therapeutics (SAGE) Gets a Hold from Truist Financial
Closing Bell Movers: Dutch Bros melts over 20% on slower new shop growth
Closing Bell Movers: Dutch Bros melts over 20% on slower unit growth
Sage Therapeutics price target lowered by $8 at Canaccord, here's why